ABBVIE

🇫🇷France
Ownership
-
Established
2013-01-01
Employees
-
Market Cap
$346B
Website
http://www.abbvie.com

Efficacy and Safety of BI 655066/ABBV-066 (Risankizumab) in Patients With Severe Persistent Asthma

Phase 2
Completed
Conditions
Interventions
First Posted Date
2015-05-13
Last Posted Date
2019-04-10
Lead Sponsor
AbbVie
Target Recruit Count
214
Registration Number
NCT02443298
Locations
🇬🇧

Wishaw General Hospital, Wishaw, United Kingdom

🇳🇱

HagaZiekenhuis, Den Haag, Netherlands

🇵🇱

Univ. Hospital in Krakow,Pulmonology Clinical Dept, Krakow, Poland

and more 61 locations

Pharmacokinetics and Safety of ABT-493 and ABT-530 in Subjects With Normal and Impaired Renal Function

Phase 1
Completed
Conditions
Interventions
First Posted Date
2015-05-13
Last Posted Date
2016-02-22
Lead Sponsor
AbbVie
Target Recruit Count
46
Registration Number
NCT02442258
Locations
🇺🇸

Site Reference ID/Investigator# 132890, Miami, Florida, United States

🇳🇿

Site Reference ID/Investigator# 137332, Grafton, Auckland, New Zealand

🇺🇸

Site Reference ID/Investigator# 132889, Orlando, Florida, United States

A Study to Assess Resistance and Durability of Response to ABT-493 and/or ABT-530

Phase 2
Completed
Conditions
Interventions
First Posted Date
2015-05-12
Last Posted Date
2020-09-21
Lead Sponsor
AbbVie
Target Recruit Count
384
Registration Number
NCT02441283
Locations
🇨🇦

Toronto Liver Centre /ID# 155401, Toronto, Ontario, Canada

🇺🇸

Digestive Health Specialists of the Southeast /ID# 136725, Dothan, Alabama, United States

🇺🇸

Southern California Res. Ctr. /ID# 141799, Coronado, California, United States

and more 39 locations

Phase 2, Multicenter, Open-Label Extension Study With ABT-122 in Rheumatoid Arthritis Subjects Who Have Completed the Preceding M12-963 Study

Phase 2
Completed
Conditions
Interventions
First Posted Date
2015-05-05
Last Posted Date
2017-07-24
Lead Sponsor
AbbVie
Target Recruit Count
158
Registration Number
NCT02433340

A Phase 2, Multicenter Open-Label Extension (OLE) Study With ABT-122 in Active Psoriatic Arthritis Subjects Who Have Completed a Preceding Study M14-197

Phase 2
Terminated
Conditions
Interventions
First Posted Date
2015-04-29
Last Posted Date
2016-06-17
Lead Sponsor
AbbVie
Target Recruit Count
168
Registration Number
NCT02429895
Locations
🇧🇬

Site Reference ID/Investigator# 138926, Plovdiv, Bulgaria

🇵🇱

Site Reference ID/Investigator# 139000, Bialystok, Poland

🇧🇬

Site Reference ID/Investigator# 138928, Sofia, Bulgaria

and more 33 locations

Special Investigation in Patients With Psoriatic Arthritis (PsA) (Working Productivity and Activity Impairment [WPAI])

Completed
Conditions
First Posted Date
2015-04-13
Last Posted Date
2018-10-16
Lead Sponsor
AbbVie
Target Recruit Count
148
Registration Number
NCT02414633

A Study Evaluating the Efficacy and Tolerability of Veliparib in Combination With Paclitaxel/Carboplatin-Based Chemoradiotherapy Followed by Veliparib and Paclitaxel/Carboplatin Consolidation in Adults With Stage III Non-Small Cell Lung Cancer (NSCLC)

First Posted Date
2015-04-09
Last Posted Date
2020-07-22
Lead Sponsor
AbbVie
Target Recruit Count
48
Registration Number
NCT02412371
Locations
🇺🇸

Rhode Island Hospital /ID# 133493, Providence, Rhode Island, United States

🇺🇸

Univ Maryland School Medicine /ID# 132944, Baltimore, Maryland, United States

🇺🇸

Dana-Farber Cancer Institute /ID# 133494, Boston, Massachusetts, United States

and more 9 locations

A Study Evaluating the Safety and Pharmacokinetics of ABBV-075 in Subjects With Cancer

First Posted Date
2015-03-18
Last Posted Date
2019-11-29
Lead Sponsor
AbbVie
Target Recruit Count
128
Registration Number
NCT02391480
Locations
🇺🇸

City of Hope /ID# 154053, Duarte, California, United States

🇺🇸

UC Davis Comp Cancer Ctr /ID# 154644, Sacramento, California, United States

🇺🇸

Indiana Univ School Medicine /ID# 132946, Indianapolis, Indiana, United States

and more 7 locations
© Copyright 2024. All Rights Reserved by MedPath